Guidepoint Qsight revealed new insights on the state of the $17.5 billion Medical Aesthetics industry. The findings highlight how the integration of glucagon-like peptide-1 (GLP-1) medications for weight loss is reshaping the Aesthetics market, fueling significant growth for practices across the U.S. Neurotoxins continued to lead by share of non-surgical aesthetics spend, with total patient spend growing by 4 percent. In contrast, surgical spend remained relatively flat in 2024, reflecting the ongoing shift toward non-surgical aesthetics. Meanwhile, GLP-1 medications continued to drive overall industry growth, with revenue at practices offering GLP-1 treatments increasing by an average of 9 percent, compared to a 2 percent decline at practices that did not offer these drugs. GLP-1 medications now contribute approximately 15 percent of monthly revenue at practices offering them, and around 40 percent of GLP-1 patients in 2024 were completely new customers to their practice. “The medical aesthetics industry is continuously evolving, with GLP-1 medications fundamentally reshaping how aesthetic practices approach patient acquisition and revenue generation,” says Erik Haines, managing director of Guidepoint Qsight. “Our data indicates that practices embracing these innovations are outpacing their peers. Weight loss spending now significantly surpasses non-energy-based device skin rejuvenation and professional grade skincare, becoming the fourth largest non-surgical aesthetics segment we track.”
Medical spas are leading the charge in offering GLP-1 treatments, with 60 percent of medical spas in the U.S. now providing these services, compared to 35 percent of aesthetic physician offices. Average spend per patient across aesthetic practices grew by 5 percent to $1,471 in 2024, indicating that consumers are increasingly willing to invest in themselves.